Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRA2A | P08913 | 2/20 | 1.00 |
| ▸ | ADRA1A | P35348 | 2/20 | 1.00 |
| ▸ | CHRM2 | P08172 | 1/20 | 1.00 |
| ▸ | HTR1A | P08908 | 1/20 | 1.00 |
| ▸ | CHRM1 | P11229 | 1/20 | 1.00 |
| ▸ | DRD1 | P21728 | 1/20 | 1.00 |
| ▸ | SLC6A2 | P23975 | 1/20 | 1.00 |
| ▸ | SLC6A4 | P31645 | 1/20 | 1.00 |
| ▸ | OPRM1 | P35372 | 1/20 | 1.00 |
| ▸ | DRD3 | P35462 | 1/20 | 1.00 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 1.00 |
| ▸ | KCNH2 | Q12809 | 1/20 | 1.00 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.97 |
| ▸ | GAA | P10253 | 1/20 | 0.97 |
| ▸ | TSHR | P16473 | 1/20 | 0.97 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.75 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.75 |
| ▸ | LMNA | P02545 | 1/20 | 0.75 |
| ▸ | MAOA | P21397 | 4/20 | 0.71 |
| ▸ | MAOB | P27338 | 4/20 | 0.71 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Mebhydrolin SCHEMBL29808874 | 1.00 | ADRA2A (1.00) | ADRA2AADRA1ACHRM2HTR1ACHRM1 | |
| Mebhydrolin SCHEMBL2141004 | 0.99 | ALDH1A1 (1.00) | ADRA2AADRA1ACHRM2HTR1ACHRM1 | |
| SCHEMBL8038611 | 0.92 | CHRM2 (0.85) | ADRA2AADRA1ACHRM2HTR1ACHRM1 | |
| SCHEMBL12938848 | 0.91 | ADRA2A (0.83) | ADRA2AADRA1ACHRM2HTR1ACHRM1 | |
| SCHEMBL3716403 | 0.91 | CHRM2 (0.83) | ADRA2AADRA1ACHRM2HTR1ACHRM1 | |
| SCHEMBL4130866 | 0.90 | HRH1 (0.82) | ADRA2AADRA1ACHRM2HTR1ACHRM1 | |
| SCHEMBL4125370 | 0.90 | CHRM2 (0.81) | ADRA2AADRA1ACHRM2HTR1ACHRM1 | |
| SCHEMBL19970051 | 0.89 | CHRM2 (0.80) | ADRA2AADRA1ACHRM2HTR1ACHRM1 | |
| SCHEMBL3621165 | 0.89 | HTR6 (0.81) | ADRA2AADRA1ACHRM2HTR1ACHRM1 | |
| SCHEMBL24630759 | 0.88 | ADRA2A (0.77) | ADRA2AADRA1ACHRM2HTR1ACHRM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1363 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12550885-B2 | Red blood cell storage solutions, solution additives, and methods for improving the storage of red blood cells | UNIVERSITY OF CINCINNATI (US) | 2026-02-17 | — | — | US | claimed |
| EP-4658278-A1 | SELECTIVE FIASMA TREATMENT | Valo Health, Inc. (US) | 2025-12-10 | — | — | EP | claimed |
| US-20250041208-A1 | NEW INJECTABLE COMBINATION FORMULATION | NANEXA AB (SE) | 2025-02-06 | — | — | US | claimed |
| EP-4444277-A1 | NEW INJECTABLE COMBINATION FORMULATION | Nanexa AB (SE) | 2024-10-16 | — | — | EP | claimed |
| WO-2024163699-A1 | SELECTIVE FIASMA TREATMENT | VALO HEALTH, INC. (US) | 2024-08-08 | — | — | WO | claimed |
| US-20230330111-A1 | ACTIVE AGENT COMBINATION FOR TREATMENT OF CANCER | Helmholtz Zentrum München - Deutsches Forschungszentrum für Gesundheit und Umwelt (GmbH) (DE) | 2023-10-19 | — | — | US | claimed |
| US-20230321008-A1 | INHIBITORS OF ACID SPHINGOMYELINASE FOR PREVENTING AND TREATING THE COVID-19 DISEASE | ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS (FR) | 2023-10-12 | — | — | US | claimed |
| CN-116660543-A | Diagnostic and prognostic markers for nonalcoholic fatty liver disease and uses thereof | 中国人民解放军陆军军医大学第一附属医院 | 2023-08-29 | — | — | CN | claimed |
| EP-4203944-A1 | ACTIVE AGENT COMBINATION FOR TREATMENT OF CANCER | Helmholtz Zentrum München Deutsches Forschungszentrum für Gesundheit und Umwelt GmbH (DE) | 2023-07-05 | — | — | EP | claimed |
| WO-2023105227-A1 | NEW INJECTABLE COMBINATION FORMULATION | NANEXA AB (SE) | 2023-06-15 | — | — | WO | claimed |
| EP-1073470-A1 | PHARMACEUTICAL COMPOSITIONS CONTAINING COMPOUNDS WITH ACTIVITY FOR THE ENHANCEMENT OF ABSORPTION OF ACTIVE INGREDIENTS | INPHARMA S.A. (CH) | 2001-02-07 | — | — | EP | claimed |
| WO-2000048636-A1 | PHARMACEUTICAL COMPOSITIONS CONTAINING COMPOUNDS WITH ACTIVITY FOR THE ENHANCEMENT OF ABSORPTION OF ACTIVE INGREDIENTS | INPHARMA S.A. (CH) | 2000-08-24 | — | — | WO | claimed |
| US-5807579-A | Pseudoephedrine combination pharmaceutical compositions | F.H. FAULDING & CO. LIMITED (AU) | 1998-09-15 | — | — | US | claimed |
| EP-0794783-A4 | CYCLODEXTRINS AS SUSPENDING AGENTS FOR PHARMACEUTICAL SUSPENSIONS | PHARMOS CORP (US) | 1998-03-04 | — | — | EP | claimed |
| EP-0794783-A1 | CYCLODEXTRINS AS SUSPENDING AGENTS FOR PHARMACEUTICAL SUSPENSIONS | PHARMOS CORPORATION (US) | 1997-09-17 | — | — | EP | claimed |
| WO-1996016659-A1 | CYCLODEXTRINS AS SUSPENDING AGENTS FOR PHARMACEUTICAL SUSPENSIONS | PHARMOS CORP. (US) | 1996-06-06 | — | — | WO | claimed |
| US-5332577-A | DRUG DELIVERY | DERMAMED (IL) | 1994-07-26 | — | — | US | claimed |
| EP-0463454-A2 | Transdermal administration to humans and animals | DERMAMED (IL) | 1992-01-02 | — | — | EP | claimed |
| US-4104382-A | (((THIAZOLYL-, ISOTHIAZOLYL- OR PYRIDYLALKYL)THIO)ALKYL)GUANIDINE | SMITH KLINE & FRENCH LABORATORIES LIMITED (GB) | 1978-08-01 | — | — | US | claimed |
| US-4000302-A | ANTIHISTAMINES | SMITH KLINE & FRENCH LABORATORIES LIMITED (EN) | 1976-12-28 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12550885-B2 | Red blood cell storage solutions, solution additives, and methods for improving the storage of red blood cells | SMPD3, SMPD4, CMA1 | ADRA2A 179/4885ADRA1A 450/4885CHRM2 100/4885 |
| US-20230321008-A1 | INHIBITORS OF ACID SPHINGOMYELINASE FOR PREVENTING AND TREATING THE COVID-19 DISEASE | SMPD2, SMPD1, SMPD3 | ADRA2A 253/4885ADRA1A 378/4885CHRM2 1663/4885 |
| US-20230330111-A1 | ACTIVE AGENT COMBINATION FOR TREATMENT OF CANCER | GLS2, AGK, GLS | ADRA2A 3436/4885ADRA1A 3160/4885CHRM2 1397/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.